MedPath

Back Pain Prevention in Multiple Myeloma Using an External Spinal Brace

Not Applicable
Completed
Conditions
Multiple Myeloma
Interventions
Device: thoracolumbosacral orthosis or cervicothoracolumbar orthosis
Other: Standard care
Registration Number
NCT02898064
Lead Sponsor
University Hospitals of North Midlands NHS Trust
Brief Summary

Consenting patients with multiple myeloma (MM) will be randomly allocated to receive either standard medical treatment (chemotherapy, radiotherapy, pain-killing medication) alone or standard medical treatment plus a brace. Patients will be regularly evaluated in research clinics; the results data will inform the design of a full trial. Information will be collected to inform a list of requirements a centre needs to have in place to run an RCT of these interventions.

Detailed Description

Multiple myeloma (MM) is a neoplasia of plasma cells mostly within the bone marrow, commonly leading to multiple vertebral collapses. This causes spinal deformity, leading to incapacitating back pain and reduced quality of life. In spite of advances in medical therapy, some patients are left with disabling back pain, sometimes requiring surgical intervention. University Hospitals of North Midlands NHS Trust have observed on an audit of our own practice that application of an external spinal brace as early in the disease process as is possible appears to maintain the overall alignment of the spine, thus minimising risk of spinal deformity and consequent back pain.

The ultimate aim is to undertake an RCT to determine whether the use of an external spinal brace can reduce back pain and spine-related disability in patients suffering from back pain due to multiple myeloma, in comparison to conventional management without a brace.

However, prior to this, a feasibility study is required. The feasibility study is needed to see if the trial processes (providing patient information, consent process, conducting the baseline investigations and outcome measures) can be accommodated without causing too much delay to the application of the brace.

Suitable patients will be consented by the research team and randomised to receive a brace or no brace in addition to their routine Myeloma treatment. After baseline data collection and questionnaires, the participant would be followed up for data collection at 6 weeks and 3 months.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
2
Inclusion Criteria
  • Adults with MM
  • Myeloma infiltration in the spine confirmed by radiological evidence
  • MM-related back pain
  • Can attend for the whole follow up period
Exclusion Criteria
  • Presenting with cord compression and neurological deficit requiring urgent decompression and intervention
  • Chronic pain syndrome
  • Language barrier that cannot be overcome using translation services
  • Unwilling or unable to give informed consent
  • Painful VCFs at the lumbosacral junction, L4 to Sacrum, where application of brace is not possible.

Not suitable for treatment with a brace e.g. pregnancy

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Standard care + braceStandard careSpinal brace (thoracolumbosacral orthosis or cervico-thoraco-lumbar orthosis) to be fitted to the participant in addition to receiving standard of care treatment which can include radiotherapy, chemotherapy or surgery including vertebral augmentation and also medication including bisphosphonates
Standard careStandard careParticipant will receive standard of care treatment which can include radiotherapy, chemotherapy or surgery including vertebral augmentation and also medication including bisphosphonates
Standard care + bracethoracolumbosacral orthosis or cervicothoracolumbar orthosisSpinal brace (thoracolumbosacral orthosis or cervico-thoraco-lumbar orthosis) to be fitted to the participant in addition to receiving standard of care treatment which can include radiotherapy, chemotherapy or surgery including vertebral augmentation and also medication including bisphosphonates
Primary Outcome Measures
NameTimeMethod
Number of appointments issued by orthotists21 months
Time from diagnosis to brace fitting for patients randomised to the intervention groupAssessed at 3 months
Are appropriate braces fitted6 weeks

The locations and levels of VCFs and back pain in patients and the type of brace fitted will be recorded to determine whether appropriate braces are fitted.

Number of patients in the intervention arm who request additional support from the orthotic team and time they had to wait for support.assessed at the end of study at 21 months
The number of orthotists in each hospital21 months
Frequency of appointments issued by orthotists21 months
Secondary Outcome Measures
NameTimeMethod
The number of patients that drop-out during follow-up and their reasons21 months
Qualitative assessment of semi structured interviews in a sub-set of participants, EQ-5D-5L21 months
The number of missing cases for a subsequent RCTs co-primary outcomes of pain and disability21 months
Pain measured by VAS6 weeks and 3 months
The number of new MM cases at each centre1 year
The number of eligible patients who give consent to enter the study21 months
Descriptive statistics and qualitative analysis of the 3-month follow up patient questionnaire3 months

The questionnaire consists principally of ordinal rating scales, which will be analysed descriptively in terms of frequencies, medians and interquartile ranges. Qualitative data from the supplementary open-ended questions will be analysed by means of framework analysis.

The number of patients who receive non-study-related interventions during the 3 month follow-up period3 months
Number of patients eligible for the study during 1 recruitment year.1 year
Disability measured by ODI6 weeks and 3 months

Trial Locations

Locations (1)

University Hospitals of North Midlands NHS Trust

🇬🇧

Stoke-on-Trent, Staffordshire, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath